EOLS - Evolus Inc logo

EOLS

Evolus Inc

Revenue grew 100% of years5Y
Hold

Evolus Inc. develops aesthetic products for the cash-pay market, including Jeuveau, a botulinum toxin formulation for glabellar lines, and Evolysse, a range of hyaluronic acid injectables targeting facial areas like lips and cheeks across several regions.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$754today

Score Overview

1 Year
Score
Net Growth33.52%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth6.50%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.4
Net Growth26.65%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth217.53%
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth26.74%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev TrendEvery year
Revenue Consistency

See the full market ranking โ†’

Evolus Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 56M to $ 297M and net income went from -$ 163M to -$ 51M. Revenue increased in every one of those 5 years; net income in 3.

Evolus Inc currently holds a 5-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 8.12โ€”
1 Year2025-08-12
$ 6.4026.87%
5 Years2021-08-12
$ 10.77-24.61%
All Time2018-02-08
$ 11.50-29.39%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 316M-$ 34M$ 45M
2025$ 297M-$ 51M$ 53M
2024$ 266M-$ 50M$ 86M
2023$ 202M-$ 61M$ 62M
2022$ 148M-$ 74M$ 53M
2021$ 99M-$ 46M$ 146M
2020$ 56M-$ 163M$ 107M
2019$ 34M-$ 90M$ 129M
IPO2018$ 0.00-$ 46M$ 93M

Explore beyond EOLS

You're looking at Evolus Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies